Tetraphase stock: buy or sell?
May 21st, 2019
Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections.
Should I buy Tetraphase stock?Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. That's why is so important to choose your own trading plan that fits your character as inversor. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
Currently, Tetraphase Pharmaceuticals stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Tetraphase Pharmaceuticals stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we detected 5 ratings published for TTPH stock in the last 30 days. The general sentiment of these ratings is bullish for TTPH stock, with 4 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-3-15||Piper Jaffray Companies||n/a||Overweight|
|2019-3-15||Piper Jaffray Companies||n/a||Overweight|
Tetraphase stock analysis
Shares of Tetraphase closed today at $0.84 and rocketed an astounding 5.00%.
Tetraphase shares rocketed 5.00% to $0.84 today. TTPH marked a lower low and a lower high in the short term, defining a downward trend. Climbing above $1.11 would break this short term down trend and open possibilities for reversing this situation.
After sliding a frightening -16.67% in a week last week, Tetraphase closed this week at $0.84 and remained steady a neutral 0.00%.
Tetraphase Pharmaceuticals finally declined under the support line and now is sliding further looking for new supports. Since price and 20-weeks moving average lines crossed down early September, TTPH fell $-2.70 per share (-76.27%).
Tetraphase stock price history
Tetraphase stock went public on March 20th, 2013 with a price of $7.201. Since then, TTPH stock lost a -88.30%, with a yearly average of -14.70%.
1: Adjusted price after possible price splits or reverse-splits.
Tetraphase stock historical price chart
TTPH stock reached 52-week highs on June at $4.49, and all-time highs 2015-07-15 with a price of 52.9.
Tetraphase stock price target is $3.80Nobody can reliably foresee how stock prices may evolve in the future. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. You should not follow the analysts' TTPH stock price predictions in the hope that they will be met as they may be wrong and not met. For the last 30 days we found 4 price forecasts for TTPH stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-5-10||SunTrust Banks||Lowers Target||n/a||$4.00||-|
|2019-3-15||Piper Jaffray Companies||Reiterates||$6.00||$4.00||-33.3%|
|2019-3-15||Piper Jaffray Companies||Lowers Target||$6.00||$4.00||-33.3%|
Financials and fundamental analysis
Earnings date and Earnings per ShareAfter presenting its last earnings report on March, Tetraphase plummed a scary -35.38%. Unfortunately, reported EPS is not yet available in our database.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual turnover report draw a super good growth of 95.57% to $18.90 million USD. In line, its income margin (compared to sales) climbed to -381.71%, that is $-72.16 million.
|2013||$10 M||-||$-29.64 M-282.6%||-|
|2014||$9.10 M||-13.27%||$-66.74 M-733.6%||125.18%|
|2015||$12 M||28.45%||$-83.19 M-711.9%||24.64%|
|2016||$5.15 M||-55.97%||$-77.48 M-1505.9%||-6.86%|
|2017||$9.67 M||87.87%||$-114.75 M-1187.2%||48.11%|
|2018||$19 M||95.57%||$-72.16 M-381.7%||-37.12%|
Quarterly financial resultsTetraphase Pharmaceuticals posted $4.28 M in revenues for 2018-Q4, a 272.20% improvement compared to previous quarter. Reported quarter income marked $-21.48 million with a profit margin of -501.42%. Profit margin boosted a 1,197.79% compared to previous quarter when profit margin was -1,699.22%. When comparing revenues to same quarter last year, Tetraphase sales marked an astounding gain and skyrocketed a 69.46%.
|2017-Q1||$1 M||-||$-29.46 M-1977.2%||-|
|2017-Q2||$2 M||6.71%||$-31.81 M-2000.6%||7.98%|
|2017-Q3||$4 M||155.79%||$-30.01 M-737.8%||-5.66%|
|2017-Q4||$3 M||-37.84%||$-23.48 M-928.6%||-21.77%|
|2018-Q1||$2 M||-25.20%||$-21.58 M-1141.0%||-8.09%|
|2018-Q2||$12 M||512.32%||$-9.54 M-82.4%||-55.77%|
|2018-Q3||$1 M||-90.06%||$-19.56 M-1699.2%||104.95%|
|2018-Q4||$4 M||272.20%||$-21.48 M-501.4%||9.83%|
Tetraphase ownershipWhen you are planning to buy shares of a stock, it's always worth to overview its ownership structure.
Tetraphase shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 0.61% of all shares.
In case of Tetraphase stock, 45.24% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for TTPH stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Tetraphase Pharmaceuticals:
|Market cap||$45.6 M||$204.3 B||$6.0 M||$230.8 B|
|Total shares||54.3 M||2,570.0 M||17.2 M||5,550.0 M|
|Float shares||53.9 M||2,570.0 M||5.3 M||5,520.0 M|
|- Institutional holdings (%)||45.2%||78.3%||4.1%||76.2%|
|- Insider holdings (%)||0.6%||0.1%||25.9%||0.0%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%|
|Tuesday, May 21st, 2019|
|Day range||$0.75 - $0.89|
|Average true range||$0.08|
|50d mov avg||$1.13|
|100d mov avg||$1.20|
|200d mov avg||$1.82|
Tetraphase performanceTo better understand Tetraphase performance you must compare its gains with other related stocks in same sector or industry. For Tetraphase Pharmaceuticals, the benchmark is made against Merck, NovaBay Pharmaceuticals and Pfizer.